Resources from the same session
255O - Darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) in the phase III ARASENS study
Presenter: Shanshan Wang
Session: Proffered Paper session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
256O - Prostate-specific antigen response to different real-world treatments in high-risk metastatic hormone-naïve prostate cancer in J-ROCK registry study
Presenter: Atsushi Mizokami
Session: Proffered Paper session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
257O - Association of enzalutamide (ENZA) duration of treatment (DOT) and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis from PREVAIL
Presenter: Edmund Chiong
Session: Proffered Paper session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 255O, 256O and 257O
Presenter: Deborah Mukherji
Session: Proffered Paper session: Genitourinary tumours
Resources:
Slides
Webcast